A “Gold Standard” Test for Diagnosing and Quantifying Hemolysis in Neonates and Infants

• Published in: Journal of perinatology Vol. 43; no. 12; pp. 1541 - 1547
• Main Authors: Christensen, Robert D., Bahr, Timothy M., Wong, Ronald J., Vreman, Hendrik J., Bhutani, Vinod K., Stevenson, David K.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.12.2023; Nature Publishing Group
• Subjects: 631/443; 692/53/2421; Anemia; Child; Diagnostic systems; Erythrocytes; Hemolysis; Humans; Hyperbilirubinemia; Infant, Newborn; Infants; Laboratory tests; Life span; Medical diagnosis; Medicine; Medicine & Public Health; Neonates; Neurotoxicity; Newborn babies; Pediatric Surgery; Pediatrics; Perspective; Risk Factors; Senescence
• ISSN: 0743-8346; 1476-5543
• DOI: 10.1038/s41372-023-01730-4

Identifying “gold standard” diagnostic tests can promote evidence-based neonatology practice. Hemolysis is a pathological shortening of the erythrocyte lifespan, differing from erythrocyte senescence in responsible mechanisms and clinical implications. Diagnosing hemolysis goes beyond a binary (yes vs . no) determination. It is characterized according to magnitude, and as acute vs . chronic, and genetically based vs . not. For neonates with significant hyperbilirubinemia or anemia, detecting hemolysis and quantifying its magnitude provides diagnostic clarity. The 2022 American Academy of Pediatrics (AAP) Clinical Practice Guideline on management of hyperbilirubinemia in the newborn states that hemolysis is a risk factor for developing significant hyperbilirubinemia and neurotoxicity. The guideline recommends identifying hemolysis from any cause, but specific guidance is not provided. A spectrum of laboratory tests has been endorsed as diagnostic methods for hemolysis. Herein we examine these laboratory tests and recommend one as the “gold standard” for diagnosing and quantifying hemolysis in neonates and infants.